NEWS

  • November 4, 2019

    Kantum Pharma Founder to Present Preclinical Data Demonstrating Beneficial Effects of P2Y14 Antagonist in Acute Kidney Injury at the American Society of Nephrology Annual Meeting

    November 4, 2019 3:30pm Eastern Daylight Time CAMBRIDGE, MA (Newswire.com) - ​Kantum Pharma Inc., a biopharmaceutical company focused on developing therapies for the prevention and treatment of d...

    Read More
  • September 12, 2019

    CroíValve Secures €4M in Additional Funding to Initiate Clinical Trials

    September 12, 2019 07:00 AM Eastern Daylight Time DUBLIN (BUSINESS WIRE)– €4 million in additional financing has been secured by CroíValve, a high potential start-up (HPSU) supported by Enterp...

    Read More
  • August 14, 2019

    Renovacor Closes $11 Million Series A Financing to Advance First Gene Therapy for a Rare Cardiovascular Disease

    August 14, 2019 07:00 AM Eastern Daylight Time PHILADELPHIA--(BUSINESS WIRE)--Renovacor, Inc, a preclinical-stage biopharmaceutical company focused on developing transformative gene therapy-...

    Read More
  • February 11, 2019

    FineHeart makes Fierce Medtech’s 2018 List

    February 11, 2019. FineHeart makes Fierce Medtech’s 2018 list of 15 exciting/innovative companies to watch. FierceMedTech’s Fierce 15 class of 2018 is aimed at advancement—whether it’s simpl...

    Read More
  • February 6, 2019

    Broadview Ventures 2018 Annual Report

    Broadview Ventures 2018 Annual Report...

    Read More
  • February 4, 2019

    Vectorious Medical Technologies Announces World’s First In-Heart Microcomputer for Left Atrial Pressure Monitoring

    Tel-Aviv, Israel (4 February, 2019) – Vectorious Medical Technologies, a medical device company enabling optimal management for heart failure patients, today announced the initiation of the VECTOR-H...

    Read More
  • December 4, 2018

    Remedy Publication: Effect of IV glyburide on adjudicated edema endpoints in the GAMES-RP Trial

    Link to publication...

    Read More
  • November 9, 2018

    ZZ Biotech Publication: Final Results of the RHAPSODY Trial

    Link to publication...

    Read More
  • November 5, 2018

    Acesion Pharma Announces Positive Results for Novel Drug Targeting Atrial Fibrillation

    COPENHAGEN, Denmark — 5 November 2018: Acesion Pharma (“Acesion” or the Company), a Danish biotech company developing novel treatments for atrial fibrillation (AF), the most common cardiac arrhy...

    Read More
  • September 18, 2018

    AtaCor Medical Raises $8.8M to Develop Substernal Cardiac Pacing System

    SAN CLEMENTE, Calif.--(BUSINESS WIRE)--AtaCor Medical, Inc. (www.atacor.com) announced today that it has completed a $8.8M Series A financing. Co-led by Boston-based Broadview Ventures and Israel-base...

    Read More